• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

cstam@unimelb.edu.au

Credentials


Position
Clinical (Professor)
Department of Medicine
Education
Doctoral Degree (Research) / PhD
University of Melbourne
Bachelors Degree (Honours)
University of Melbourne
ORCID

0000-0002-9759-5017

Prof Constantine Tam

Clinical (Professor)
Department of Medicine

930 Scholarly works
7 Projects

HIGHLIGHTS

  • 2022

    Journal article

    Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
    DOI: 10.1182/blood.2022016040
  • 2022

    Journal article

    Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
    DOI: 10.1182/bloodadvances.2022008325
  • 2022

    Journal article

    Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
    DOI: 10.1182/blood.2021012775
  • 2022

    Journal article

    Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
    DOI: 10.1182/bloodadvances.2021005621
  • 2022

    Research grants (ARC, NHMRC, MRFF)

    Understanding and Averting Blood Cancer Resistance to Therapy
  • 2019

    Research grants (ARC, NHMRC, MRFF)

    The Aim2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma
  • 2017

    Research Grant

    Centre of Research Excellence in Chronic Lymphotic Leukemia at the Victorian Comprehensive Cancer Centre
Constantine Tam

Latest Honours,
Awards and Fellowships


2013
Herman Clinical Fellow of Cancer Research University of Melbourne
2010
Teaching Excellence Award University of Melbourne
2009
Clinical Investigator Fellowship Sylvia and Charles Viertel Foundation
2008
Merit Award American Society of Clinical Oncology

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    First-line treatment for CLL in the era of targeted therapy
    DOI: 10.1038/s41408-025-01434-2
  • 2026

    Journal article

    Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
    DOI: 10.1182/bloodadvances.2026020123
  • 2026

    Journal article

    Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy.
    DOI: 10.1182/bloodadvances.2026020197
  • 2026

    Journal article

    Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.
    DOI: 10.1182/bloodadvances.2026021618
  • 2026

    Journal article

    Risk-Guided Disease Management to Prevent Heart Failure in Adult Cancer Survivors of Previous Cardiotoxic Cancer Treatments (REDEEM) Trial
    DOI: 10.1016/j.hlc.2026.07.008
  • 2026

    Journal article

    Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment
    DOI: 10.1016/j.bneo.2026.100260
  • 2026

    Journal article

    Australasian chronic lymphocytic leukaemia consensus statement: 2026 update
    DOI: 10.1111/imj.70503
  • 2026

    Journal article

    Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study
    DOI: 10.1111/bjh.70620

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224